WO2006132907A3 - Procedes de traitement, de diagnostic ou de detection du cancer - Google Patents

Procedes de traitement, de diagnostic ou de detection du cancer Download PDF

Info

Publication number
WO2006132907A3
WO2006132907A3 PCT/US2006/021246 US2006021246W WO2006132907A3 WO 2006132907 A3 WO2006132907 A3 WO 2006132907A3 US 2006021246 W US2006021246 W US 2006021246W WO 2006132907 A3 WO2006132907 A3 WO 2006132907A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
diagnosing
treating
ephb3
modulator
Prior art date
Application number
PCT/US2006/021246
Other languages
English (en)
Other versions
WO2006132907A2 (fr
Inventor
Deborah Lee Zimmerman
Mary Jo Janatpour
Original Assignee
Novartis Vaccines & Diagnostic
Deborah Lee Zimmerman
Mary Jo Janatpour
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic, Deborah Lee Zimmerman, Mary Jo Janatpour filed Critical Novartis Vaccines & Diagnostic
Priority to EP06771814A priority Critical patent/EP1888648A2/fr
Priority to AU2006255536A priority patent/AU2006255536A1/en
Priority to JP2008514843A priority patent/JP2008545750A/ja
Priority to CA002610685A priority patent/CA2610685A1/fr
Publication of WO2006132907A2 publication Critical patent/WO2006132907A2/fr
Publication of WO2006132907A3 publication Critical patent/WO2006132907A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

La présente invention a trait, entre autres, à des procédés pour le traitement du cancer, à des compositions pour le traitement du cancer, et à des procédés et des compositions pour le diagnostic et/ou la détection du cancer. En particulier, la présente invention a trait à des compositions et des procédés pour le traitement, le diagnostic et la détection des cancers associés à la surexpression de EphB3.
PCT/US2006/021246 2005-06-03 2006-06-02 Procedes de traitement, de diagnostic ou de detection du cancer WO2006132907A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP06771814A EP1888648A2 (fr) 2005-06-03 2006-06-02 Procedes de traitement, de diagnostic ou de detection du cancer
AU2006255536A AU2006255536A1 (en) 2005-06-03 2006-06-02 Methods of treating, diagnosing or detecting cancer using an EphB3 modulator
JP2008514843A JP2008545750A (ja) 2005-06-03 2006-06-02 Ｅｐｈｂ３モジュレーターを使用する、癌を処置、診断または検出するための方法
CA002610685A CA2610685A1 (fr) 2005-06-03 2006-06-02 Procedes de traitement, de diagnostic ou de detection du cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68742905P 2005-06-03 2005-06-03
US60/687,429 2005-06-03

Publications (2)

Publication Number Publication Date
WO2006132907A2 WO2006132907A2 (fr) 2006-12-14
WO2006132907A3 true WO2006132907A3 (fr) 2007-05-18

Family

ID=37311854

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/021246 WO2006132907A2 (fr) 2005-06-03 2006-06-02 Procedes de traitement, de diagnostic ou de detection du cancer

Country Status (5)

Country Link
EP (1) EP1888648A2 (fr)
JP (1) JP2008545750A (fr)
AU (1) AU2006255536A1 (fr)
CA (1) CA2610685A1 (fr)
WO (1) WO2006132907A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101437188B1 (ko) * 2006-08-04 2014-10-02 노바르티스 아게 Ｅｐｈｂ3-특이적 항체 및 이의 용도
WO2008070780A1 (fr) 2006-12-07 2008-06-12 Novartis Ag Anticorps antagonistes contre ephb3

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4233782A1 (de) * 1992-10-07 1994-04-14 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Klonierung eines neuen Mitgliedes der Familie der Rezeptor-Protein-Tyrosin-Kinasen
WO2002000728A2 (fr) * 2000-06-26 2002-01-03 Gpc Biotech Inc. Procedes et compositions permettant d'isoler des anticorps presentant une activite biologique
WO2003004057A1 (fr) * 2001-07-03 2003-01-16 The Hospital For Sick Children Immunomodulation induite par les recepteurs ephrin et eph
WO2004005457A2 (fr) * 2002-07-08 2004-01-15 Kylix B.V. Utilisation de genes cibles specifies tcf permettant d'identifier des medicaments pour le traitement du cancer, plus particulierement du cancer colorectal, la signalisation tcf/$g(b)-catenine-wnt jouant un role fondamental
WO2005031002A2 (fr) * 2003-09-22 2005-04-07 Rosetta Inpharmatics Llc Ecran letal synthetique par interference arn
WO2006023403A2 (fr) * 2004-08-16 2006-03-02 Medimmune, Inc. Variants fc de liaison a un recepteur eph presentant une activite cytotoxique cellulaire dependant des anticorps
WO2006056467A1 (fr) * 2004-11-25 2006-06-01 Cellzome Ag Utilisation d'inhibiteurs du recepteur eph pour le traitement de maladies neurodegeneratives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0208089D0 (en) 2002-04-09 2002-05-22 Oxford Glycosciences Uk Ltd Protein

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4233782A1 (de) * 1992-10-07 1994-04-14 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Klonierung eines neuen Mitgliedes der Familie der Rezeptor-Protein-Tyrosin-Kinasen
WO2002000728A2 (fr) * 2000-06-26 2002-01-03 Gpc Biotech Inc. Procedes et compositions permettant d'isoler des anticorps presentant une activite biologique
WO2003004057A1 (fr) * 2001-07-03 2003-01-16 The Hospital For Sick Children Immunomodulation induite par les recepteurs ephrin et eph
WO2004005457A2 (fr) * 2002-07-08 2004-01-15 Kylix B.V. Utilisation de genes cibles specifies tcf permettant d'identifier des medicaments pour le traitement du cancer, plus particulierement du cancer colorectal, la signalisation tcf/$g(b)-catenine-wnt jouant un role fondamental
WO2005031002A2 (fr) * 2003-09-22 2005-04-07 Rosetta Inpharmatics Llc Ecran letal synthetique par interference arn
WO2006023403A2 (fr) * 2004-08-16 2006-03-02 Medimmune, Inc. Variants fc de liaison a un recepteur eph presentant une activite cytotoxique cellulaire dependant des anticorps
WO2006056467A1 (fr) * 2004-11-25 2006-06-01 Cellzome Ag Utilisation d'inhibiteurs du recepteur eph pour le traitement de maladies neurodegeneratives

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
EASTY D J ET AL: "Protein tyrosine kinases in malignant melanoma", MELANOMA RESEARCH, vol. 10, no. 5, October 2000 (2000-10-01), pages 401 - 411, XP009075785, ISSN: 0960-8931 *
FARIVAR ROBERT SAEID ET AL: "The efficacy of tyrosine kinase inhibitors on human pancreatic cancer cell lines.", JOURNAL OF SURGICAL RESEARCH, vol. 115, no. 2, December 2003 (2003-12-01), pages 219 - 225, XP001180012, ISSN: 0022-4804 *
LIU W ET AL: "COEXPRESSION OF EPHRIN-BS AND THEIR RECEPTORS IN COLON CARCINOMA", CANCER, AMERICAN CANCER SOCIETY, PHILADELPHIA, PA, US, vol. 94, no. 4, 15 February 2002 (2002-02-15), pages 934 - 939, XP001156840, ISSN: 0008-543X *
SCHWARTZ DONALD R ET AL: "Novel candidate targets of beta-catenin/T-cell factor signaling identified by gene expression profiling of ovarian endometrioid adenocarcinomas.", CANCER RESEARCH, vol. 63, no. 11, 1 June 2003 (2003-06-01), pages 2913 - 2922, XP002410754, ISSN: 0008-5472 *
See also references of EP1888648A2 *

Also Published As

Publication number Publication date
AU2006255536A1 (en) 2006-12-14
WO2006132907A2 (fr) 2006-12-14
CA2610685A1 (fr) 2006-12-14
EP1888648A2 (fr) 2008-02-20
JP2008545750A (ja) 2008-12-18

Similar Documents

Publication Publication Date Title
WO2008011519A3 (fr) Inhibiteurs d'amigo-2 pour le traitement, le diagnostic ou la détection du cancer
WO2008061020A3 (fr) Méthodes permettant de traiter, de diagnostiquer ou de détecter un cancer
WO2007120787A3 (fr) Procede de traitement, de diagnostic ou de detection du cancer
AU2016204376A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
WO2007053573A3 (fr) Traitement du cancer au moyen de sorafenib
WO2007061874A3 (fr) Procedes et compositions utilises dans le traitement du cancer
WO2007134210A8 (fr) Méthodes et compositions destinées au diagnostic et au traitement du cancer
WO2009036427A3 (fr) Biomarqueurs du cancer de la prostate
WO2007016548A3 (fr) Procedes et compositions a base de micro-arn pour le diagnostic, le pronostic et le traitement du cancer du sein
WO2007081740A3 (fr) Méthodes et compositions basés sur des micro-arn et s'appliquant au diagnostic et au traitement de cancers solides
WO2009005809A3 (fr) Compositions et procédés de traitement et de diagnostic d'un cancer
WO2006089125A3 (fr) Méthodes de détection du cancer de l'ovaire
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
WO2008124660A3 (fr) Procédés et compositions pour le traitement du cancer
WO2010009337A3 (fr) Signatures et déterminants de la pc associés au cancer de la prostate et leurs procédés d’utilisation
WO2007059041A3 (fr) Combinaisons et methodes d'utilisation d'un oligonucleotide immunomodulatoire
WO2008094708A3 (fr) Antagonistes de l'activine-actriia et leurs utilisations dans le traitement ou la prévention du cancer du sein
TW200732349A (en) Anti-OX40L antibodies and methods using same
WO2008094545A3 (fr) Méthodes et compositions à base de micro-arn pour le diagnostic, le pronostic et le traitement de la leucémie aiguë myéloïde (lam)
WO2007149482A3 (fr) Traitement du cancer à base de xanthohumol par modulation de la protéine kinase
WO2002080754A3 (fr) Methodes d'utilisation d'une annexine permettant de visualiser la mort cellulaire in vivo et de traiter des etats pathologiques
WO2008002672A3 (fr) Cibles utilisées pour le diagnostic, le pronostic et la thérapie du cancer
WO2009092108A3 (fr) Biomarqueurs pour le diagnostic et le traitement du cancer du pancréas
WO2008008923A3 (fr) Compositions et procédés pour cibler des complexes de transcription spécifiques du cancer
WO2007025303A3 (fr) Antiandrogenes non steroidiens

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2610685

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006255536

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2008514843

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006771814

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006255536

Country of ref document: AU

Date of ref document: 20060602

Kind code of ref document: A